



WBB Securities, LLC

Press Release

Steve Brozak, WBB President, speaks at NY Biotechnology Association Annual Meeting

San Diego, CA and Westfield, NJ (May 20, 2008) – Steve Brozak spoke at the New York Biotechnology Association on Monday May 19, and participated in a panel titled Using Bio-defense Initiatives to Drive Drug Discovery and Development. Mr. Brozak’s remarks, titled A Forward Looking Strategy for Biotech Businesses in the Bioshield/BARDA Arena, focused on the unique opportunities and challenges biotechnology businesses face when doing business in the federal government arena.

Mr. Brozak’s remarks were based on the premise that the biotechnology business environment is the most challenging the industry has faced. He pointed out that new drug approvals are down, development costs are up and the investment environment is cautious. He also explained that in addition to the normal success factors for a biotechnology business, working with the federal government requires a special set of competencies.

Slides from Mr. Brozak’s presentation are available upon request.

* * *

Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

* * *